New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
As average credit card APRs soar past 20%, a proposed 10% rate cap ignites a fierce debate between consumer advocates and the banking industry over access to credit and the future of rewards.
Oracle's deepening role as TikTok's U.S. data guardian and its aggressive push into regulated AI sectors present a dual narrative of strategic growth and heightened operational scrutiny, following a service outage linked to its infrastructure.
Altria Group expects improved second-half earnings by leveraging a U.S. tobacco tax rebate tied to increased exports, as the Marlboro maker seeks new avenues for growth in a shrinking cigarette market.
Cocoa futures have plunged to multi-year lows, pressured by a global surplus and weakening demand as high chocolate prices curb consumption. Analysts point to favorable harvests in West Africa and falling processing volumes as key factors extending the market's month-long decline.
Gold prices soared to a historic peak above $5,500 an ounce this week, fueled by Fed policy signals, only to plunge dramatically as a resurgent U.S. Dollar and profit-taking sparked a broad retreat. The volatile swing sets a tense stage for the metal as markets await key economic data.
Panera Bread confirms a second major data security incident in two years, while Krispy Kreme agrees to a $1.6 million settlement over a 2024 breach, as the foodservice industry grapples with escalating cyber threats and consumer lawsuits.
President Trump's reported selection of former Fed Governor Kevin Warsh to lead the central bank signals a potential shift in monetary policy approach, with a focus on strategic foresight over data-dependency, according to economist Mohamed El-Erian.
With low adoption rates for brokerage 'trusted contacts,' regulators are considering a simple name change to 'emergency contact' to reduce confusion, ease client concerns, and strengthen protections against financial exploitation.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
In remarks that now appear pointed, Fed Chair Jerome Powell robustly defended the central bank's personnel and economic frameworks just days before former Governor Kevin Warsh, a vocal critic, was nominated to potentially succeed him.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Royal Caribbean Group (RCL) reported strong fourth-quarter results, meeting revenue expectations with a 13.3% year-over-year increase to $4.26 billion. The cruise giant's performance, driven by record passenger volumes and strategic investments, signals robust health in the leisure travel sector.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Shares of Cushman & Wakefield have surged 35.8% in six months, dramatically outpacing the broader market. While strong quarterly results fueled the climb, a deeper look at the firm's long-term financial health reveals potential headwinds that could give investors pause.
Shares of restaurant operator Bloomin' Brands have tumbled over 35% in six months, raising questions about its financial health and growth trajectory as analysts flag significant risks.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
Usama Ghanem, an Egyptian student at King's College London, faces imminent deportation after disciplinary action linked to his pro-Palestinian activism. He claims the university's response mirrors the political persecution he fled in Egypt, raising urgent questions about academic freedom and the treatment of international dissent.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
